Repeal the medical marijuana oversight committee.
HB 1160 repeals the statutory sections that created and governed South Dakota’s medical marijuana oversight committee. Under current law, that committee is made up of legislators, medical professionals, law enforcement, a counselor or addiction counselor, and a qualifying patient, and it is required to meet at least twice a year to review how the medical cannabis program is working and to make recommendations to the Legislature and the Department of Health. The bill would eliminate those duties and the committee structure entirely.
As a result, the measure would remove a formal legislative-advisory body that has been tasked with monitoring patient access, dispensary and cultivation operations, testing facilities, security safeguards, regulatory changes, and medical research related to medical cannabis. The repeal would affect the oversight framework in South Dakota’s medical cannabis laws, but it would not itself rewrite the underlying medical marijuana program, licensing system, or patient eligibility rules.
HB 1160 would amend South Dakota Codified Laws by repealing §§ 34-20G-92, 34-20G-92.1, and 34-20G-93, thereby ending the statutory medical marijuana oversight committee and its reporting and recommendation responsibilities. The practical effect would be to reduce formal legislative oversight of the medical cannabis program and remove a required venue for stakeholder input from patients, caregivers, public safety officials, medical providers, and cannabis businesses. The bill would leave the broader medical marijuana framework in place unless other statutes are separately changed.
The bill appears to have generated mixed but active support, with several procedural votes showing enough backing to advance it, including a House do-pass vote of 41-26. At the same time, the committee and floor history also show repeated deferrals and a close Senate committee vote of 15-19 against do pass, suggesting substantial concern or disagreement. Overall, the discussion reflected a divided chamber rather than broad consensus.
The main point of contention is whether South Dakota should keep a dedicated oversight committee for the medical marijuana program. Supporters of repeal likely view the committee as unnecessary bureaucracy or duplicative oversight, while opponents likely see it as an important mechanism for monitoring patient access, program safety, pricing, testing, and regulatory issues. The committee’s composition, which includes legislators, health professionals, law enforcement, and a qualifying patient, suggests the debate also centers on whether those stakeholder perspectives should remain formally built into the law.